Cargando…

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan

BACKGROUND: Biosimilar granulocyte colony-stimulating factor (G-CSF) has recently been introduced into clinical practice. G-CSFs are used to mobilize CD34(+) cells and accelerate engraftment after transplantation. However, in Asia, particularly in Japan, data for peripheral blood stem cell (PBSC) mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshimura, Hideaki, Hotta, Masaaki, Nakanishi, Takahisa, Fujita, Shinya, Nakaya, Aya, Satake, Atsushi, Ito, Tomoki, Ishii, Kazuyoshi, Nomura, Shosaku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279847/ https://www.ncbi.nlm.nih.gov/pubmed/28182150 http://dx.doi.org/10.2147/JBM.S123374

Ejemplares similares

Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma
por: Nomura, Shosaku, et al.
Publicado: (2018)

Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report
por: FUJITA, YUKIE, et al.
Publicado: (2016)

Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma
por: Nakaya, Aya, et al.
Publicado: (2016)

Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia
por: Nakaya, Aya, et al.
Publicado: (2018)

Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era
por: Nakaya, Aya, et al.
Publicado: (2017)

Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents
por: Nakaya, Aya, et al.
Publicado: (2017)

Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection
por: Nakaya, Aya, et al.
Publicado: (2017)

Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide
por: Ito, Tomoki, et al.
Publicado: (2018)

Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia
por: Hotta, Masaaki, et al.
Publicado: (2018)

Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study
por: Ito, Tomoki, et al.
Publicado: (2018)

Human T-cell Leukemia Virus Type I Associated with an Increased Risk of Primary Malignant Neoplasm
por: Nakaya, Aya, et al.
Publicado: (2018)

Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
por: Takeyasu, Yuki, et al.
Publicado: (2017)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
por: Konishi, Akiko, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma
por: Azuma, Yoshiko, et al.
Publicado: (2019)

Retrospective analysis of adolescent and young adult with lymphoma at two cancer facilities in Japan
por: Nakaya, Aya, et al.
Publicado: (2019)

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting
por: Nakaya, Aya, et al.
Publicado: (2020)

Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era
por: Nakaya, Aya, et al.
Publicado: (2019)

Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia
por: AZUMA, YOSHIKO, et al.
Publicado: (2016)

Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review
por: Hotta, Masaaki, et al.
Publicado: (2021)

Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement: A Case Report with Literature Review
por: Nakanishi, Takahisa, et al.
Publicado: (2020)

Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis
por: Gardellini, A, et al.
Publicado: (2013)

A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptoms
por: Nakanishi, Takahisa, et al.
Publicado: (2019)

Myodesopsia is a symptom of central nervous system blast crisis in chronic myeloid leukemia
por: Ishii, Kazuyoshi, et al.
Publicado: (2019)

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting
por: Ito, Tomoki, et al.
Publicado: (2019)

Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors
por: Schmitt, M, et al.
Publicado: (2013)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation
por: Ozasa, Ryotaro, et al.
Publicado: (2012)

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli, Désirée, et al.
Publicado: (2016)

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
por: Sevinç, Alper, et al.
Publicado: (2018)

Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product
por: Halim, Liem Andhyk, et al.
Publicado: (2018)

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019)

Primary dural high grade B cell lymphoma mimicking subdural hematoma
por: Nakaya, Aya, et al.
Publicado: (2021)

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.
por: O'Brien, M. E., et al.
Publicado: (1994)

Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β(1), and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia
por: Nomura, Shosaku, et al.
Publicado: (2018)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
por: Kamioner, Didier, et al.
Publicado: (2013)

Six cases of autoimmune acquired coagulation factor VIII deficiency: Single center experience in Japan
por: Konishi, Akiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ljanc5t7mj4v0utjt1d3dc0afc